Investor Relations

Company Overview

Virax Biolabs is a Biotech and disruptive Medical Technology company focused on the prevention, detection and diagnosis of Viral threats. Our mission is the global provision of high-quality diagnostic kits, particularly T-Cell tests, which accurately and effectively predict an individual's immune response to significant viral threats. Our proprietary diagnostic T-cell technologies are virus agnostic, offering high levels of transparency, information and insight in a cost-efficient way. Key product ranges include ViraxClear, ViraxCare and flagship product being released 2022, Virax Immune.

IR Contacts

Headquarters

Virax Biolabs Group Limited
30 Broadwick Street
London W1F 8JB
United Kingdom
T: +44 20 7788 7414
info@viraxbiolabs.com

Investor Relations

Skyline Corporate Communications Group, LLC
Scott Powell
One Rockefeller Plaza
11th Floor
New York, NY 10020
M: 646-893-5835
scott@skylineccg.com

Transfer Agent

Continental Stock Transfer
Charlotte Hewitt
1 State Street
30th Floor
New York, NY 10004
T: 212-857-7577
chewitt@continentalstock.com